Use of a Kappa-carrageenan Nasal Solution in the Prophylaxis Treatment of Respiratory Infection Against Viruses Influenza (H1N1), Coronavirus (SARS-CoV-2) and Chronic Obstructive Pulmonary Diseases (COPD)
replication (genome copy number) was quantified, tissue integrity was measured. Epithelia (MucilAir™-Pool) cells were used for the study. The experiment was designed to test the antiviral effects of kappa

